AUR 200
Alternative Names: AUR-200Latest Information Update: 09 Sep 2024
At a glance
- Originator Thunderbolt Pharma
- Developer Aurinia Pharmaceuticals
- Class Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Discontinued Kidney disorders